

Rules for IMI project communications

Catherine Brett

02.04.2019 • IMI project communications workshop • Brussels

We want you to be creative but...

... there are rules!

All project communications must include...

- A formal acknowledgement of IMI's support
- A link to the IMI website – www.imi.europa.eu
- IMI, EU, EFPIA, Associated Partner logos
- A disclaimer

No need to take notes – all info is in the IMI project communications guide on the IMI website!

Acknowledgement of IMI support

IMI2 projects – communication activities

This project has received funding from the **Innovative Medicines Initiative 2** Joint Undertaking under grant agreement No [xxxxx]. This Joint Undertaking receives support from the **European Union's** Horizon 2020 research and innovation programme and **EFPIA** [and [insert names of **Associated Partners**]]

IMI2 projects – infrastructure, equipment and major results

This [infrastructure][equipment][insert type of result] is part of a project that has received funding from the **Innovative Medicines Initiative 2** Joint Undertaking under grant agreement No [xxxxx]. This Joint Undertaking receives support from the **European Union's** Horizon 2020 research and innovation programme and **EFPIA** [and [insert names of **Associated Partners**]].



Acknowledgement of IMI support

IMI1 projects (all communications and products)

The research leading to these results has received support from the **Innovative Medicines Initiative** Joint Undertaking under grant agreement n° [xxxxxx], resources of which are composed of financial contribution from the **European Union's** Seventh Framework Programme (FP7/2007-2013) and **EFPIA** companies' in kind contribution.

Limited space? Use the short version

This work has received support from the **EU/EFPIA/[Associated Partner] Innovative Medicines Initiative** [2] Joint Undertaking ([Project Acronym] grant n° [xxxxxx]).

Logos



innovative
medicines
initiative




innovative
medicines
initiative



**Associated
Partners**

Link to the IMI website

www.imi.europa.eu




We are an EU public-private partnership funding health research and innovation

€5.3bn BUDGET	113 PROJECTS	2225 PARTICIPANTS	>7 000 PROJECT OUTPUTS	>3 800 PUBLICATIONS
-------------------------	------------------------	-----------------------------	-------------------------------------	----------------------------------

LATEST NEWS

IMI Stakeholder Forum 2019 - registration open

Registration is now open for the IMI Stakeholder Forum 2019, which will be held in Brussels on 12 June. The theme of this year's event is 'Brain health and disease in the digital era - 2020 & beyond'. We will explore ways of building IMI Call topics that converge around this relatively new space and which could open up new channels where fresh voices and minds will join established players in the field...



The PRO-active project: support for patients with respiratory diseases

'We brought target binding kinetics to the international research community' – an interview with the K4DD project coordinators

IMI launches IMI2 - Call 17



A disclaimer

It should be made clear in the text and layout that the communication reflects the author's view and that neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained therein.


Best practice

AIMS-2-TRIALS website

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.



Hypo-RESOLVE website



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 777460. The JU receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and T1D Exchange, JDRF, International Diabetes Federation (IDF), The Leona M. and Harry B. Helmsley Charitable Trust.

Best practice

These projects have received funding from the Innovative Medicines 2 Joint Undertaking under grant agreements for EBOVAC1 (grant no. 115854), EBOVAC2 (grant no. 115861). This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
www.imi.europa.eu



EBOVAC1/2 poster

EPAD brochure

The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies' in kind contribution. More information can be found at www.imi.europa.eu



MOPEAD infographic



This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No 115985. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations. © 2016 MOPEAD.

Best practice

RESOLUTE on Twitter

RESOLUTE_IMI

@RESOLUTE_IMI Follows you

The RESOLUTE-IMI consortium aims to trigger an escalation in the appreciation and intensity of research on solute carriers transporters (SLCs) worldwide.

📍 This work has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (RESOLUTE grant No 777372).

🌐 re-solute.eu

ELF video



"The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115489, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7 / 2007-2013) and EFPIA companies' in kind contribution. "

ADAPTED scientific journal article

Funding

This work was partly supported by the CoSTREAM consortium, which has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No 667375, and the ADAPTED consortium, which has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115975. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation program and the European Federation of Pharmaceutical Industries and Associations.

EQIPD newsletter



Copyright © EQIPD 2018 Powered by ECNP

This project has received funding from the [Innovative Medicines Initiative 2 Joint Undertaking](#) under grant agreement No 777364. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

This newsletter reflects only the authors' views neither IMI JU nor EFPIA nor the European Commission are liable for any use that may be made of the information contained therein.

Last but not least...

Keep your website,
social media, news
page, newsletters,
etc. up to date!



Thank you

Catherine Brett • External Relations Manager
catherine.brett@imi.europa.eu

www.imi.europa.eu



@IMI_JU